{"id":27854,"date":"2021-12-20T18:00:22","date_gmt":"2021-12-20T18:00:22","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/?p=27854"},"modified":"2023-05-24T12:53:24","modified_gmt":"2023-05-24T12:53:24","slug":"information-relative-a-lanreotide-aux-etats-unis","status":"publish","type":"post","link":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/general-fr\/information-relative-a-lanreotide-aux-etats-unis\/","title":{"rendered":"Information relative \u00e0 lanr\u00e9otide aux Etats Unis"},"content":{"rendered":"\n
PARIS, FRANCE, 20 D\u00e9cembre 2021 \u2013 18 :00 CET<\/strong> \u2013 Ipsen a appris que Cipla Limited et sa filiale Cipla USA, Inc. ont re\u00e7u l\u2019approbation finale de la Food and Drug Administration am\u00e9ricaine pour un produit lanr\u00e9otide ; l\u2019approbation de la FDA \u00e9tait bas\u00e9e sur une New Drug Application (NDA) soumise dans le cadre de la proc\u00e9dure de d\u00e9p\u00f4t 505(b)(2). Il n\u2019y a pas de changement dans les perspectives financi\u00e8res \u00e0 moyen terme d\u2019Ipsen \u00e0 2024.<\/p>\n","protected":false},"excerpt":{"rendered":" PARIS, FRANCE, 20 D\u00e9cembre 2021 \u2013 18 :00 CET \u2013 Ipsen a appris que Cipla Limited et sa filiale Cipla USA, Inc.<\/p>\n","protected":false},"author":9,"featured_media":19250,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3542,1215],"tags":[],"class_list":["post-27854","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mediastatement-fr","category-general-fr","entry"],"acf":[],"yoast_head":"\n